Skip to main content
Fig. 4 | BMC Infectious Diseases

Fig. 4

From: A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years

Fig. 4

Subjects* reporting reactogenicity events within 4 days of receiving the MenACWY-TT booster. Both local and general reactogenicity events by intensity and the primary vaccine group are shown. Intensity scales are summarized in Additional File 1: Table S1. GI gastrointestinal, MenACWY meningococcal A, C, W, Y, PS polysaccharide, TT tetanus toxoid

*In the booster total vaccinated cohort for safety

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us